Trial purpose
Cancer treatment
Tumor type
Genitourinary
Age
18+
Trial acronym
KEYMAKER-U04
Clinical summary
Summary
This study is recruiting people with locally advanced or metastatic urothelial carcinoma who have not had any prior treatment for their locally advanced or metastatic disease. People may be eligible if they have had certain treatments for earlier stage disease, please speak to your doctor regarding eligibility. Eligible participants will be randomly allocated to one of three treatment arms. In Arm A (Experimental), participants will receive co-formulated immunotherapy (favezelimab/pembrolizumab) as an intravenous (IV) infusion on Day 1 of every 3-week cycle for up to ~2 years, plus the antibody-drug conjugate enfortumab vedotin as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, toxicity or investigator decision. In Arm B (Experimental), participants will receive co-formulated immunotherapy (vibostolimab/pembrolizumab) as an IV infusion on Day 1 of each 3-week cycle, for up to ~2 years, plus the antibody-drug conjugate enfortumab vedotin as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, toxicity or investigator decision. In Arm C (Active Comparator), participants will receive immunotherapy (pembrolizumab) as an IV infusion on Day 1 of every 3-week cycle for up to ~2 years, plus the antibody-drug conjugate enfortumab vedotin as an IV infusion on Days 1 and 8 of every 3-week cycle, until disease progression, intolerable toxicity or investigator decision.
Conditions
This trial is treating people with locally advanced or metastatic urothelial cancer
Eligibility
Inclusion
-
Must have histologically documented, locally advanced/metastatic urothelial carcinoma (la/mUC).
- Participants with mixed histology are eligible provided the urothelial component is ≥50% (and <10% plasmacytoid component)
- Participants whose tumors contain any neuroendocrine component are not eligible (variant histology to be confirmed locally)
-
Must not have received prior systemic therapy for la/mUC. The following therapies in earlier disease setting (eg, muscle-invasive urothelial carcinoma (MIUC)) are permitted:
- Participants that received neoadjuvant or adjuvant chemotherapy are permitted.
- Participants who received anti- programmed cell death 1 protein (PD-1) or programmed cell death ligand 1 (PD-L1) therapy for an earlier disease stage (eg, NMIBC, MIUC) with progression/recurrence >12 months from completion of therapy are permitted.
- Must provide an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion demonstrating UC, not previously irradiated, and adequate for biomarker evaluation. A newly obtained biopsy is strongly preferred, but not required if archival tissue is evaluable.
- Any AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Endocrine-related AEs adequately treated with hormone replacement or with <Grade 2 neuropathy are eligible.
Exclusion
- Has a known additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy.
- Central nervous system (CNS) metastases are permitted on-study if all of the following are true: a) CNS metastases have been clinically stable for at least 4 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis; b) the participant is on a stable dose of ≤10 mg/day of prednisone or equivalent for at least 2 weeks (if requiring steroid treatment); c) participant does not have leptomeningeal disease.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
- Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention. Inhaled or topical steroids are permitted in the absence of active autoimmune disease. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency.
- Has active keratitis or corneal ulcerations. Superficial punctate keratitis is allowed if the disorder is being adequately treated in the opinion of the investigator.
- Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy.
- Has a history of uncontrolled diabetes.
- Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
- Has an active infection (viral, bacterial, or fungal) requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has hepatitis B or hepatitis C virus infection.
- Has had major surgery within 4 weeks prior to first dose of study intervention.
- Has had an allogenic tissue/solid organ transplant
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
- You have been diagnosed with cancer, but have not received any treatment.
Exclusion
- You are currently being treated on a clinical trial.
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Merck Sharp & Dohme LLC
Scientific Title
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information